A research study centered on magic mushrooms in Canada has revealed that nearly 80% of participants are of the opinion that psilocybin, a compound found in magic mushrooms, should be medically available for distressed patients. Moreover, about two-thirds of the Canadian participants from the same study concur that psilocybin should be legally accessible to those in need.
Beyond merely making the substance more accessible, a significant 84.8 percent of participants opine that the public health system should bear the costs of such treatments. According to the majority of Canadians, psilocybin represents a credible alternative, particularly for treating end-of-life distress.
[toc]
Key Takeaways:
- Residents from Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical option for dealing with end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants from two double-blind trials reported immediate and long-lasting benefits, with effects persisting for six months or more.
Defining Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may undergo feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. This form of distress is especially prevalent among patients with life-threatening illnesses, potentially leading them to hasten death or contemplate suicide.
Generally, individuals confronted with terminal diseases or significant life changes are those most likely to experience this type of distress. It severely impacts their mental health and overall life quality.
Existential therapy attempts to tackle issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy may require many sessions and might not prove effective for everyone.
The uncertainty associated with the effectiveness of such therapy is a major reason why many individuals seek alternative treatments.
Health Canada’s Stance on Using Psilocybin as a Therapeutic Option
In the past two decades, preliminary clinical trials have highlighted the promising benefits of psychedelic substances for treating complex mental disorders. Specifically, Psilocybin has demonstrated a fast and long-lasting relief from existential distress in patients who are approaching the end of their lives.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are ineffective, Health Canada revised the Special Access Program in 2022. This revision permits healthcare professionals to request controlled substances for their patients.
Canadian Support for Access to Psilocybin
A research study published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Survey of 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these respondents had prior use of psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% support the public health system offering this therapy. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings are in line with surveys conducted in Canada, England, and Australia. The researchers underscored the uniqueness of their study as it focuses on utilizing psychoactive substances for alleviating existential distress in end-of-life situations.
Why Canadians Support the Use of Psilocybin
An increasing number of Canadians are endorsing the use of psilocybin as a therapeutic option, mainly due to the compelling evidence from esteemed research institutions. Another factor is the perceived safety of psilocybin mushrooms for easing existential distress. Participants in various studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Methodology | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and sustained |
| The benefits of the therapy can last up to six months or even more. The efficacy of the therapy is primarily due to mystical experiences that involve a deep sense of unity and profound emotional enlightenment. | ||
| Trial at New York University | A group of 29 patients were randomly chosen to receive either psilocybin or the active placebo niacin | The results of the study echoed the findings of the Johns Hopkins study. Patients who received psilocybin reported psychological relief and a refreshed perspective on life and death. |
| BMC Palliative Care | Seven doctors, four active nurses, four chaplains, three social workers, and a psychologist – a total of nineteen participants – were interviewed. The objective of the study was to understand how professionals in palliative care perceive existential distress and their perspective on psychedelic therapy as a potential treatment. | Palliative care practitioners commented that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Beyond scientific studies, the effectiveness of psilocybin is also supported by numerous patient narratives that highlight its ability to enhance mental health and the quality of life.
The Journey of Yokoi
Mio Yokoi, who was suffering from terminal stage 4 pancreatic cancer, shares a transformative experience during her assisted therapy. She visualized herself on a raft, surrounded by nature and accompanied by imaginative creatures. This vision instilled in her a profound understanding of the universe’s interconnectedness and support, leading to a sense of immense peace and affirmation.
Even with conventional mental health support, Yokoi continued to struggle with severe anxiety and distress following her diagnosis. Psilocybin therapy aided her in re-establishing a connection with her body and provided a tangible sense of love and support. This significantly improved her mental and emotional health.
Story of Chrissy
Chrissy, a woman in her 50s, was battling stage 4 breast cancer that had metastasized to her lungs. At the time of the study, she was working full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant decreases in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked about any changes in her religious or spiritual beliefs post-therapy, she mentioned that the experiences had infused her beliefs with deeper meaning and authenticity.
Brenda’s Journey
Brenda, a lady in her mid-60s, was diagnosed with stage I colon cancer. During her screening, it was discovered she had no history of hallucinogen use and she met the criteria for Chronic Adjustment Disorder accompanied by Anxiety.
In the course of her therapy, Brenda experienced the sensation of dying twice. However, she came out of these experiences without a fear of death, seeing it as a beautiful aspect of the cycle of life. She credits the research study for initiating her healing process from childhood trauma. Her responses and feedback reflected this significant transformation.
It is noteworthy that a decrease in anxiety and fear of death, coupled with an increase in spirituality, were observed.
Availability of Magic Mushroom Products in Canada
At present, access to psilocybin capsules and other similar products intended to alleviate existential distress or other mental health conditions may be limited. Nevertheless, reliable online dispensaries can provide these products when needed.
| Features | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and its neighboring South American countries. | Discovered in Cambodia, specifically around the Angkor Wat Temple. | Related to the Penis Envy mushroom strain, which became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Similarly moderate in potency; perfect for those just starting out. | Exceptionally potent; recommended for individuals with intermediate to advanced experience. |
| Effects | Causes a mental buzz, minor disorientation, enhanced color perception, feelings of euphoria, spiritual experiences, heightened creativity, and improved concentration. | Initiates a long-lasting, invigorating high, minor visual distortions, increased creativity, euphoria, a gentle physical high, fractal imagery, and sensations of joy. | Induces deep shamanic experiences, vision quests, intense mystical experiences, elevated creativity, concentration, social consciousness, and mood enhancement. |
Using Psilocybin Products to Ease End-of-life Discomfort
Existential or end-of-life distress can exert a significant burden on many patients nearing the end of their lives. Traditional treatments for this distress may not always be effective, leading to an increase in Canadian support for more accessible magic mushrooms within public healthcare. This growing public interest could
We advocate for regulatory authorities to acknowledge the potential of magic mushrooms as a valid treatment option. Obtain your psychedelics and mushroom delivery from Shrooms For Sale Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The experiences of patients undergoing Psychedelic-assisted therapy (PAT) can greatly differ, and it’s crucial to carefully prepare and follow particular steps to secure a positive outcome. A rigorous screening and mental readiness are required before the intake of the substance.
- Pre-Session Preparation: Patients are subject to a detailed assessment. The therapist will discuss the patient’s goals and expectations to set the session’s aims. The patient will also be informed about the process’s effect and what to expect during the session.
- The Session: A regulated dose of the substance is administered to patients in a serene, distraction-free environment to promote relaxation and self-reflection. The therapist offers ongoing support and direction during this time.
- Post-Session Integration Therapy: This therapy helps patients make sense of and process their experiences. Follow-up sessions provide continual support and advice to reinforce the knowledge and changes attained during therapy.
How does psilocybin affect the brains of patients in distress?
By binding to serotonin receptors, specifically the 5-HT2A receptor, it interacts with the brain. This interaction can cause changes in perception, mood, and cognition, leading to significant consciousness shifts, emotional disclosures, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Patients with certain mental health conditions or existential distress are meticulously screened to exclude those with a history of psychosis.
Articles of Interest:
